Home / WVE : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does WVE make money? Does WVE have pricing power? What's the Earnings Whisper? Will WVE profit more as the business scales? What is WVE's management track record? Is WVE's current price justified?

Wave Life Sciences Ltd.

$4.5 -$11.45 (-71.79%)

NASDAQ · 14 Sep 2026 14:45 UTC

Previous Close

$4.59

Day Range

$4.49$4.63

Year Range

$4.49$21.73

Market Cap

886.72M

AVG Volume

3.35M

Trailing/Forward PE

-4.14/-

PEG ratio

-0.24

Dividend Yield

Next Earnings Date

2026-11-09

Primary Exchange

NASDAQ

Revenue (USD) · TTM

WVE Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
26 Q2	65.37M
26 Q1	71.8M
25 Q4	42.73M
25 Q3	109.23M
25 Q2	93.95M
25 Q1	104.94M
24 Q4	108.3M
24 Q3	53.61M
24 Q2	110.5M
24 Q1	112.91M

Net Income (USD) · TTM

WVE Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-202.47M
26 Q1	-183.59M
25 Q4	-204.38M
25 Q3	-121.95M
25 Q2	-129.87M
25 Q1	-112.33M
24 Q4	-97.01M
24 Q3	-142.52M
24 Q2	-73.48M
24 Q1	-61.67M

Operating Income (USD) · TTM

WVE Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-217.92M
26 Q1	-196.88M
25 Q4	-215.38M
25 Q3	-135.95M
25 Q2	-143.51M
25 Q1	-125.75M
24 Q4	-110.4M
24 Q3	-152.05M
24 Q2	-83.69M
24 Q1	-72.17M

EBITDA (USD) · TTM

WVE EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-197.54M
26 Q1	-174.59M
25 Q4	-195.53M
25 Q3	-113.2M
25 Q2	-121.2M
25 Q1	-103.68M
24 Q4	-88.34M
24 Q3	-133.83M
24 Q2	-65.08M
24 Q1	-54.14M

Cash Flows (USD) · TTM

WVE Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-186.24M
26 Q1	-183.34M
25 Q4	-186.55M
25 Q3	-198.17M
25 Q2	-200.12M
25 Q1	-181.32M
24 Q4	-151.96M
24 Q3	-141.82M
24 Q2	-129.62M
24 Q1	-139.43M

EPS (USD) · TTM

WVE EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-1.09
26 Q1	-1.06
25 Q4	-1.22
25 Q3	-0.75
25 Q2	-0.9
25 Q1	-0.84
24 Q4	-0.79
24 Q3	-1.11
24 Q2	-0.57
24 Q1	-0.52

Expenses (USD) · TTM

WVE Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	284.85M
26 Q1	269.66M
25 Q4	258.82M
25 Q3	245.98M
25 Q2	238.4M
25 Q1	231.37M
24 Q4	219.64M
24 Q3	206.87M
24 Q2	195.22M
24 Q1	186.13M

Shares Outstanding · TTM

WVE Shares Outstanding · TTM by quarter
Period	Shares Outstanding · TTM
26 Q2	-26.27M
26 Q1	-21.73M
25 Q4	-17.62M
25 Q3	-20.86M
25 Q2	-17.92M
25 Q1	-15.21M
24 Q4	-13.14M
24 Q3	-12.25M
24 Q2	-11M
24 Q1	-9.93M

Employee Count

WVE Employee Count by quarter
Period	Employee Count
2025	317
2024	287
2023	266
2022	250
2021	235
2020	217
2019	301
2018	250
2017	168
2016	96

Free Cash Flow Yield

WVE Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-20.08%
Sep 26	-18.96%
Aug 26	-18.28%
Aug 26	-17.42%
Aug 26	-17.03%
Aug 26	-15.11%
Jul 26	-16.72%
Jul 26	-15.76%
Jul 26	-15.74%
Jul 26	-14.65%
Jul 26	-14.63%
Jun 26	-15.71%
Jun 26	-14.87%
Jun 26	-15.6%
Jun 26	-15.98%
May 26	-13.92%
May 26	-14.36%
May 26	-13.53%
May 26	-12.76%
May 26	-12.51%
Apr 26	-14.42%
Apr 26	-13.83%
Apr 26	-14.42%
Apr 26	-14.22%
Mar 26	-16.26%
Mar 26	-8.81%
Mar 26	-7.95%
Mar 26	-7.89%
Feb 26	-7.43%
Feb 26	-8.76%
Feb 26	-9.32%
Feb 26	-8.78%
Jan 26	-9.13%
Jan 26	-8.77%
Jan 26	-8.66%
Jan 26	-8.54%
Jan 26	-7.41%
Dec 25	-6.65%
Dec 25	-7.39%
Dec 25	-7.13%
Dec 25	-15.77%
Nov 25	-15.22%
Nov 25	-16.76%
Nov 25	-16.69%
Nov 25	-15.53%
Oct 25	-13.5%
Oct 25	-17.12%
Oct 25	-15.63%
Oct 25	-16.06%
Oct 25	-17.07%
Sep 25	-17.95%
Sep 25	-17.71%
Sep 25	-17.51%
Sep 25	-14.72%
Aug 25	-12.71%
Aug 25	-12.02%
Aug 25	-12.5%
Aug 25	-15.08%
Aug 25	-14.14%
Jul 25	-13.28%
Jul 25	-13.38%
Jul 25	-14.49%
Jul 25	-16.05%
Jun 25	-16.73%
Jun 25	-16.98%
Jun 25	-16.05%
Jun 25	-15.45%
May 25	-18.56%
May 25	-18.75%
May 25	-17.62%
May 25	-16.93%
May 25	-11.62%
Apr 25	-13.98%
Apr 25	-15.9%
Apr 25	-16.66%
Apr 25	-15.61%
Mar 25	-10.92%
Mar 25	-9.81%
Mar 25	-9.21%
Mar 25	-10.01%
Feb 25	-10.21%
Feb 25	-9.69%
Feb 25	-9.98%
Feb 25	-9.66%
Jan 25	-9.33%
Jan 25	-8.98%
Jan 25	-9.82%
Jan 25	-9.35%
Jan 25	-7.99%
Dec 24	-8.36%
Dec 24	-7.99%
Dec 24	-8.03%
Dec 24	-7.07%
Nov 24	-7.15%
Nov 24	-7.01%
Nov 24	-7.32%
Nov 24	-6.09%
Nov 24	-7.24%
Oct 24	-6.93%
Oct 24	-6.54%

Price to Sales

WVE Price to Sales by quarter
Period	Price to Sales
Sep 26	14.19
Sep 26	15.03
Aug 26	15.58
Aug 26	16.35
Aug 26	16.73
Aug 26	18.86
Jul 26	17.03
Jul 26	16.2
Jul 26	16.23
Jul 26	17.42
Jul 26	17.45
Jun 26	16.25
Jun 26	17.17
Jun 26	16.37
Jun 26	15.97
May 26	18.34
May 26	17.79
May 26	18.87
May 26	20.02
May 26	20.41
Apr 26	30.27
Apr 26	31.58
Apr 26	30.27
Apr 26	30.7
Mar 26	26.86
Mar 26	49.58
Mar 26	54.9
Mar 26	55.32
Feb 26	58.73
Feb 26	20.72
Feb 26	19.47
Feb 26	20.65
Jan 26	19.87
Jan 26	20.69
Jan 26	20.96
Jan 26	21.25
Jan 26	24.49
Dec 25	27.29
Dec 25	24.54
Dec 25	25.43
Dec 25	11.5
Nov 25	11.92
Nov 25	10.83
Nov 25	10.87
Nov 25	13.72
Oct 25	15.78
Oct 25	12.45
Oct 25	13.63
Oct 25	13.27
Oct 25	12.48
Sep 25	11.87
Sep 25	12.03
Sep 25	12.17
Sep 25	14.47
Aug 25	16.76
Aug 25	17.72
Aug 25	17.04
Aug 25	14.12
Aug 25	15.06
Jul 25	13.01
Jul 25	12.92
Jul 25	11.93
Jul 25	10.76
Jun 25	10.33
Jun 25	10.18
Jun 25	10.76
Jun 25	11.18
May 25	9.31
May 25	9.22
May 25	9.8
May 25	10.21
May 25	12.08
Apr 25	10.04
Apr 25	8.83
Apr 25	8.42
Apr 25	8.99
Mar 25	12.85
Mar 25	14.3
Mar 25	15.24
Mar 25	14.02
Feb 25	25.92
Feb 25	27.29
Feb 25	26.51
Feb 25	27.39
Jan 25	28.37
Jan 25	29.45
Jan 25	26.95
Jan 25	28.3
Jan 25	33.13
Dec 24	31.63
Dec 24	33.13
Dec 24	32.95
Dec 24	37.44
Nov 24	37.02
Nov 24	16.73
Nov 24	16.02
Nov 24	19.27
Nov 24	16.21
Oct 24	16.94
Oct 24	17.95

Price to Book

WVE Price to Book by quarter
Period	Price to Book
Sep 26	2.05
Sep 26	2.17
Aug 26	2.25
Aug 26	2.36
Aug 26	2.41
Aug 26	2.72
Jul 26	2.46
Jul 26	2.27
Jul 26	2.28
Jul 26	2.44
Jul 26	2.45
Jun 26	2.28
Jun 26	2.41
Jun 26	2.3
Jun 26	2.24
May 26	2.57
May 26	2.5
May 26	2.65
May 26	2.81
May 26	2.86
Apr 26	2.46
Apr 26	2.56
Apr 26	2.46
Apr 26	2.49
Mar 26	2.18
Mar 26	4.03
Mar 26	4.46
Mar 26	4.49
Feb 26	4.77
Feb 26	18.17
Feb 26	17.08
Feb 26	18.11
Jan 26	17.43
Jan 26	18.14
Jan 26	18.38
Jan 26	18.64
Jan 26	21.48
Dec 25	23.93
Dec 25	21.52
Dec 25	22.3
Dec 25	10.09
Nov 25	10.45
Nov 25	9.49
Nov 25	9.54
Nov 25	9.26
Oct 25	10.64
Oct 25	8.4
Oct 25	9.2
Oct 25	8.95
Oct 25	8.42
Sep 25	8.01
Sep 25	8.11
Sep 25	8.21
Sep 25	9.76
Aug 25	11.3
Aug 25	11.95
Aug 25	11.49
Aug 25	9.53
Aug 25	10.16
Jul 25	7.95
Jul 25	7.89
Jul 25	7.28
Jul 25	6.57
Jun 25	6.31
Jun 25	6.22
Jun 25	6.57
Jun 25	6.83
May 25	5.69
May 25	5.63
May 25	5.99
May 25	6.23
May 25	6.24
Apr 25	5.19
Apr 25	4.56
Apr 25	4.35
Apr 25	4.65
Mar 25	6.64
Mar 25	7.39
Mar 25	7.88
Mar 25	7.25
Feb 25	9.29
Feb 25	9.79
Feb 25	9.5
Feb 25	9.82
Jan 25	10.17
Jan 25	10.56
Jan 25	9.66
Jan 25	10.15
Jan 25	11.88
Dec 24	11.34
Dec 24	11.88
Dec 24	11.82
Dec 24	13.42
Nov 24	13.28
Nov 24	420.37
Nov 24	402.69
Nov 24	484.29
Nov 24	407.4
Oct 24	425.67
Oct 24	451

No video analysis for this stock yet. Request one from our team.

News: WVE

globenewswire.com · 3 Sep 2026

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

247wallst.com · 13 Aug 2026

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.

seekingalpha.com · 11 Aug 2026

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

globenewswire.com · 10 Aug 2026

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Redomiciliation”).

globenewswire.com · 5 Aug 2026

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.

globenewswire.com · 4 Aug 2026

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in August.

marketbeat.com · 30 Jul 2026

WAVE Life Sciences Q2 Earnings Call Highlights

WAVE Life Sciences NASDAQ: WVE reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026.

seekingalpha.com · 30 Jul 2026